Governments must make tackling AMR worth pharmacy's while

Pharmaceutical companies won ’t develop fast, cheap and effective diagnostic tools on their own — they need incentives to tackle antimicrobial resistance.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research